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Abstract
We present the case of an 85-year-old woman who sustained a subtrochanteric femoral shaft 
insufficiency fracture after receiving bisphosphonate therapy for osteoporosis. After more than 6 
years of taking risedronate sodium (Actonel) and daily supplemental calcium carbonate and vitamin 
D, the patient developed right anterior thigh pain that was worse with weight-bearing. A small, 
pyramidal ridge of cortical bone was demonstrated by radiographs and CT along the antero-lateral 
subtrochanteric region of the right femoral shaft. On MRI, there was focally increased T2 signal in the 
adjacent bone marrow. Radionuclide bone scan showed moderately-intense, focally-increased uptake. 
The lesion was recognized as a potential stress riser for fracture; however, before a prophylactic 
intramedullary rod could be placed, the patient suffered a low-energy insufficiency fracture through 
the lesion. In the setting of bisphosphonate therapy for osteoporosis, a painful pyramidal projection of 
cortical bone in the subtrochanteric femoral shaft should be recognized as an impending insufficiency 
fracture and treated expeditiously. 
Introduction
We present the case of an insufficiency fracture of the proximal femoral shaft in an 85-year-old 
woman who was receiving bisphosphonate therapy to reduce the fracture risk secondary to severe 
osteoporosis which was likely multi-factorial in etiology with advanced age, postmenopausal state, 
and prolonged use of glucocorticoid medications all likely being contributory. This fracture is 
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identical in presentation and appearance to other cases of insufficiency fractures of the proximal 
femoral shaft described in patients who developed severe suppression of bone turnover with 
prolonged oral bisphosphonate therapy. Abnormal bone remodeling due to prolonged osteoclast 
suppression appears to lead to insufficiency fractures of the subtrochanteric femoral shaft. It is ironic 
that medications known to increase bone density by decreasing the activity of osteoclasts, could in 
certain patients, contribute to severe suppression of bone turnover characterized by inadequate 
remodeling and the formation of insufficiency fractures. 
Case Report
An 85-year-old woman presented with limp and anterior right thigh pain. After more than 6 years of 
taking risedronate sodium (Actonel) at a dose of 35mg/week, as well as supplemental calcium 
carbonate and Vitamin D, the patient complained of 2-3 months of persistent anterior right thigh pain 
that was worse with weight bearing. This pain was different from previous episodes of pain related to 
spinal stenosis and polymyalgia rheumatica. Her past medical history was significant for osteoporosis 
with prior fractures of the pelvis, spine, and both ankles, polymyalgia rheumatica, and disc 
degeneration with spinal stenosis. She had taken oral corticosteroids for polymyalgia rheumatica for 
many years with a daily dose alternating between 7.5 and 10 mg of prednisone. On physical exam, her 
pain was non-radiating, and her gait was antalgic. Initially, an MRI was performed at an outside 
institution, and the patient was subsequently referred to our institution for further evaluation. The 
MRI report described focally increased T2 signal in the right lateral femur. At our institution, a CT 
was performed as well as radiographs, and a bone scan. Radiographic evaluation of the femur 
demonstrated a focal pyramidal-shaped projection of bone on the lateral cortex (Fig. 1). The bone 
scan performed following injection Tc99m methylene disphosphonate (MDP) (Fig. 2) revealed a 
moderately-intense focus of increased uptake at the subtrochanteric region of the right femur and a 
degenerative pattern of activity in the spine, shoulders, knees, and wrists without evidence of other 
lesions concerning for metastatic disease. CT demonstrated a focal beak of cortical thickening on the 
lateral cortex (Fig. 3), and 3-dimensional reformations showed the lesion to be a domed roughly-
pyramidal ridge, similar to a volcano such as Mt. Rainier (Fig 4). Although no fracture line was 
evident, this lesion was recognized as potential riser for fracture and the patient was referred to 
orthopedics. The patient hesitated at their recommendation for biopsy and prophylactic placement of 
an intramedullary rod to prevent fracture completion. 
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Figure 1. 85-year-old woman on bisphosphonate therapy. Radiographic evaluation of the femur 
demonstrated mild, diffuse cortical thickening and a focal, domed, conical, projection along the lateral 
cortex (arrow). 
Figure 2. 85-year-old woman on bisphosphonate therapy. Tc99m MDP bone scan shows a focus of 
moderately intense uptake at the subtrochanteric region of the right femur (arrows) and a degenerative 
pattern of activity in the spine, shoulders, knees, and wrists, without evidence of metastatic disease. 
Figure 3. 85-year-old woman on bisphosphonate therapy. 3D surface rendered CT reformation 
demonstrates the cortical ridge at the antero-lateral aspect of the femur at the junction of the proximal 
and middle thirds (arrow). 
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Figure 4. The volcanic mountain peak, Mt. Rainier, as viewed from Puget Sound offshore Seattle, 
Washington. (Courtesy Mahesh Thapa, M.D., starvingphotographer.com.) 
Nearly one month later, on her way to an appointment to discuss additional treatment options for this 
lesion, the patient stumbled on a curb. With this minimal trauma, the insufficiency fracture completed. 
Radiographs of the fracture showed a severely-angulated, simple, transverse, subtrochanteric femoral 
shaft fracture at the junction of the proximal and middle thirds (Fig 5).  Following closed reduction, 
the fracture is seen to extend through the middle of the cortical ridge seen on the earlier radiograph 
(Fig. 6). 
Figure 5. 85-year-old woman on bisphosphonate therapy. Post-fracture radiograph depicts a severely-
angulated, simple, transverse, subtrochanteric femoral shaft fracture at the junction of the proximal 
and middle thirds that extends through the middle of the triangular cortical ridge seen on the earlier 
studies. Old, healed fractures of the superior and inferior rami of the left obturator ring are also 
evident (arrows). 
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Figure 6. 85-year-old woman on bisphosphonate therapy. Proximal femoral shaft fracture following 
closed reduction of the marked angular deformity, the simple transverse fracture extends through the 
beak-shaped region of the insufficiency fracture (arrow). Mild diffuse cortical thickening is also 
present. 
The patient underwent surgical reduction and internal fixation. A relatively long and thick 
reconstruction nail with two pins in the femoral neck was utilized due to the osteoporotic 
capaciousness of her intramedullary canal and to prevent formation of proximal femoral neck and 
distal femoral shaft stress risers which could lead to subsequent fractures. At the time of surgery, a 
curetted bone specimen was obtained by reaming for intramedullary rod placement. Histological 
examination of this specimen confirmed the absence of malignant disease. 
Due to prolonged bisphosphonate usage and both chronic and ongoing glucocorticoid use, she was 
considered at risk for poor fracture healing, and her medications were adjusted to optimize healing. 
Medical necessity required that her steroid medication be continued; however, her bisphosphonate 
medication, risedronate sodium (Actonel), was discontinued. Her calcium and vitamin D 
supplementation were continued unchanged, and an anabolic agent, recombinant human parathyroid 
hormone, teriparatide (Forteo), was initiated at 20 micrograms daily by subcutaneous injection. 
Follow up radiographs of the fracture site obtained ten (Fig. 7) and nineteen weeks (Fig. 8) after 
surgery demonstrated abundant fracture callus and were deemed consistent with appropriate interval 
fracture healing. The patient has recovered uneventfully. 
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Figure 7. 85-year-old woman on bisphosphonate therapy. Subtrochanteric femur fracture 10 weeks 
post operative fixation with an 11mm x 40cm reconstruction rod with 75 and 85mm screws 
proximally and a 65 mm locking screw distally (not included in this image). Exuberant callus is 
present at the fracture site (arrows). 
Figure 8. 85-year-old woman on bisphosphonate therapy. Subtrochanteric femur fracture 19 weeks 
post operative fixation. (A) AP and lateral (B) lateral views with exuberant callus at the fracture site 
(arrows) in the proximal femoral diaphysis, compatible with appropriate healing. 
Discussion
The femoral shaft is the strongest portion of the most resilient bone in the body, and therefore, 
subtrochanteric shaft fracture is associated with violent force or underlying bony abnormality to 
include tumor, Paget disease, excessive exercise, hypophosphatemic osteomalacia, pycnodysostosis, 
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fluorosis, or severe osteoporosis. [1-9] Osteoporotic femoral fractures are associated with a higher 
degree of comminution [10]. 
In 2005, Odvina et al. identified a group of 9 patients who developed spontaneous non-spinal 
fractures while on long-term alendronate. These non-traumatic fractures involved skeletal areas rich 
in cortical bone such as the femoral shaft, pubic bone, and ischium, and were considered atypical for 
osteoporotic fractures [11]. Bone biopsies in all demonstrated severe suppression of bone turnover 
(SSBT). The patients also on estrogen or glucocorticoids presented with fractures after a shorter 
duration of bisphosphonate therapy. Post-fracture continuation of bisphosphonate therapy was also 
associated with delayed fracture healing [11]. 
In 2007, an apparent increase in the number of subtrochanteric femur fractures in women between the 
ages of 50 and 70, many of whom had received alendronate for 3 or more years prompted Goh et al. 
to further evaluate these fractures. In a series of 13 patients with low energy subtrochanteric fractures, 
patients on alendronate had a higher incidence of simple transverse or short oblique fractures (89%) 
as opposed to the patients with osteoporosis not receiving bisphosphonates (0%) [12]. Approximately 
55-76% of the patients with bisphosphonate-related fractures had prodromal pain prior to fracture 
completion whereas none of the patients with fractures due solely to severe osteoporosis in the 
absence of long-term alendronate had prodromal pain [12, 13]. Their further retrospective review 
determined a radiographically-identifiable insufficiency fracture configuration characterized by focal, 
lateral cortical thickening of the subtrochanteric femur with subsequent development of a transverse 
fracture through the lesion [13]. Additionally, 53% had bilateral findings of stress reaction or fracture 
[13]. 
In 2008, Neviaser et al. evaluated 70 low energy fractures of the femoral shaft and identified that the 
simple transverse fracture pattern with unicortical beak was 98% specific for alendronate use and was 
more likely to be seen in patients with long term use; an average of 6.9 years of alendronate use in 
patients with this fracture type compared with 2.5 years in patients on alendronate but not displaying 
this fracture pattern [15]. 
In 2008, Visekruna et al. described severely suppressed bone turnover (SSBT) and atypical skeletal 
fragility with proximal femoral metadiaphyseal/subtrochanteric fractures in 3 patients on long term 
bisphosphonate therapy, all three of whom were receiving another medication (estrogen, 
glucocorticoid, or raloxifene) that likely further suppressed bone remodeling beyond the effect of the 
alendronate alone [16]. Given the prolonged residence time of bisphosphonate medications in bone, 
their non-metabolized nature, and their ability to cause irreversible osteoclast failure, Visekruna et al. 
raise concern that although beneficial in most patients, certain susceptible patients may experience 
atypical skeletal fragility related to oral bisphosphonates, particularly when administered with other 
anti-remodeling agents. They further suggested a potential role for teriparatide to facilitate fracture 
healing in this scenario of suppressed bone remodeling [16]. Recombinant human parathyroid 
hormone PTH (1-34); teriparatide (Forteo) can be systemically administered to increase bone as it 
promotes osteoblastogenesis and decreases osteoblast apoptosis [17-19]. 
After postmenopausal and senile osteoporosis, glucocorticoid-induced osteoporosis is the third most 
common etiology of osteoporosis [20]. Common expressions of glucocorticoid-induced osteoporosis 
include fractures of the spine and ribs and osteonecrosis of the femoral heads [20]. Glucocorticoid 
medications contribute to osteopenia by several mechanisms, including early osteoclast stimulation 
and chronic osteoblast suppression [19]. It seems reasonable that teriparatide, may be beneficial in 
cases of glucocorticoid-induced osteoporosis and has been demonstrated to increase bone density in 
these patients [18]. 
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There is potential for insufficiency fractures in patients on long term, high dose, or IV 
bisphosphonates; particularly if there are other co-administered medications or factors that inhibit 
bone remodeling. In the setting of bisphosphonate therapy for osteoporosis, a painful pyramidal 
projection of cortical bone in the subtrochanteric femoral shaft should be recognized as an 
impending/incomplete insufficiency fracture and treated expeditiously to reduce the risk of fracture 
completion. 
It is necessary to balance the important benefit of bisphosphonate therapy in osteoporotic against the 
potential risk of over-suppression and subsequent insufficiency fracture. Optimal protocols for the 
dosage and duration of bisphosphonate therapy and preferred clinical management of a patient with an 
impending or completed insufficiency fracture while on bisphosphonates or other anti-remodeling 
medications deserve additional consideration. Because bisphosphonates are not metabolized, have a 
long dwell time, and may adversely affect fracture healing in some patients for months or even years 
after discontinuation, additional steps in addition to bisphosphonate discontinuation may be needed to 
promote fracture healing [11, 21, 22, 23, 24, 25]. 
This case is a paradigm of a new pattern of fractures noted in patients on bisphosphonates. It 
demonstrates characteristic radiographic features which may help identify patients at risk for 
impending fractures and suggests a possible role for teriparatide in treatment. Our patient appears to 
represent a “textbook presentation” of insufficiency fracture related to prolonged bisphosphonate 
medication on a background of severe glucocorticoid-induced osteoporosis. She presented with 
prodromal pain, a volcano-shaped conical ridge at the lateral subtrochanteric femur, and a subsequent 
simple transverse fracture with low energy mechanism. These findings are not characteristic of an 
osteoporotic fracture (due to the prodromal pain and lack of comminution), nor is the subtrochanteric 
femur a standard site for glucocorticoid-induced complications which primarily involve fractures of 
the ribs and spine, and osteonecrosis of the femoral head. 
This case further highlights a paucity of data addressing the clinical management of these lesions. It is 
unknown which patients will best benefit from prophylactic placement of an intramedullary rod to 
prevent fracture completion and in which cases a less-invasive pharmaceutical modality may achieve 
fracture healing. Given our current understanding of this syndrome of insufficiency fracture in the 
setting of severely suppressed bone turnover, the discontinuation of bisphosphonate medication, and 
use of teriparatide seem to be the best actions; however, in years to come, more information will 
certainly refine the understanding and management of these patients. 
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